Supporting information

The file contains a table with statistical analyses showing effects of analysed risk factors on survival endpoints, it also contains a schematic depiction of the trial treatment for better illustration and a graph showing the timing of occurrence of dose limiting toxicities, showing the early dominance of non-hematologic toxicities.

Supplementary table

Table S1.

	PFS			OS		
	Exp(B)	95% CI	p value*	Exp(B)	95% CI	p value*
Gene mutations						
ATM (yes vs no)	1·86	0·80-4·34	0·14	0·80	0·21-2·99	0·74
BIRC3 (yes vs no)	2·43	0·56-10·54	0·22	2·52	0·31-20·42	0·37
NFKBIE (yes vs no)	1·31	0·39-4·43	0·66	2·84	0·71-11·35	0·12
NOTCH1 (yes vs no)	2·03	0·88-4·72	0·092	3·75	1·00-14·02	0·035
SF3B1 (yes vs no)	0·41	0·06-3·05	0·37	0·97	0·12-7·80	0·98
TP53 (yes vs no)	2·39	0·55-10·32	0·23	13·55	2·40-76·63	<0·0001
ZNF292 (yes vs no)	1·10	0·33-3·74	0·87	1·91	0·39-9·29	0·42
FISH cytogenetics (high risk vs low risk)**	2·33	1·03-5·26	0·037	1·94	0·25-7·30	0·32
IgVH (unmutated vs mutated)	3·90	1·41-10·80	0·005	5·27	0·64-43·13	0·084
≥2 mutations (yes vs no)	3·35	1·00-0·07	0·051	4·06	1·01-16·26	0·032
MRD neg after induction (yes vs no)	0·33	0·14-0·77	0·007	0·53	0·12-2·39	0·40

*(Log Rank (Mantel-Cox))

** high risk defined by presence of del 17p and/or del11q, low risk defined as non-high risk

Supplementary figures



Figure S1. Trial design.



Figure S2. Occurrence of first dose limiting toxicity (DLT) per patient, as assessed at the end of treatment cycle (induction).